← Back to Home

BioNTech cancer vaccine BNT113 misses key efficacy endpoint; survival benefit remains to be verified

BNT113 combined with immunotherapy failed to significantly extend progression-free survival in patients with head and neck cancer. The trial will continue tracking overall survival, but analysts’ confidence in its eventual success has been shaken.

By SURL BioNews

Can helping the immune system recognize cancer cells also help patients live longer? BioNTech’s investigational mRNA cancer vaccine BNT113 has suffered a setback in a pivotal trial: adding it to an existing immunotherapy failed to significantly extend the time patients lived without their disease worsening. However, the trial is not yet over, and whether it can extend overall survival remains the next question to be answered.

BioNTech announced on October 13 that the phase 2/3 AHEAD-MERIT trial, which compared BNT113 plus pembrolizumab (brand name Keytruda) with pembrolizumab alone as first-line treatment, did not meet its primary endpoint of progression-free survival (PFS). Participants had unresectable, recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma, and their tumors had to express PD-L1 with a combined positive score (CPS) of at least 1. According to BioSpace, the trial enrolled 358 people.

BNT113 uses a fixed-antigen design, with mRNA encoding the HPV16 E6 and E7 proteins to induce an immune response against these virus-associated tumor antigens. It is a therapeutic cancer vaccine, with a different purpose from vaccines that prevent HPV infection. The rationale behind its development is for this immune response to work alongside pembrolizumab’s activity to improve anticancer effects. However, the biological rationale still needs to be confirmed by clinical results.

Missing this endpoint does not mean the entire trial has been declared a failure. PFS measures the time before disease progression or death, while overall survival (OS) directly tracks how long patients live. AHEAD-MERIT lists both as dual primary endpoints. Under the prespecified statistical design, a statistically significant improvement in OS could still constitute a positive trial result even though the PFS endpoint was not met. An independent data monitoring committee has recommended that the trial continue, and BioNTech said the company remains blinded to the accumulating trial data.

Market confidence in this path has weakened. BioSpace cited an analysis by BMO Capital Markets stating that the PFS setback substantially reduced its confidence in a subsequent OS benefit. However, vaccine-induced immune responses may deepen over time, leaving open the possibility that a survival benefit could emerge later. BioPharma Dive separately reported that Leerink analyst Daina Graybosch had already been cautious about the outcome, citing factors including limited early supporting evidence and the trial’s inclusion of patients with lower PD-L1 expression. These are analysts’ assessments and cannot yet be regarded as explanations for this result.

The results announced so far remain preliminary. BioNTech has not yet provided median PFS for the two groups, a hazard ratio or a full safety comparison, leaving outside observers unable to determine the size of the efficacy difference or adequately assess the benefits and burdens of adding the treatment. The next OS analysis will determine whether BNT113 can provide evidence of longer survival despite the lack of a significant improvement in disease control. Until then, this setback should be interpreted within the scope of this specific vaccine, cancer type and combination therapy, and cannot be used to draw direct conclusions about the prospects of all mRNA cancer vaccines.

References

  1. Fierce Biotech
  2. BioNTech
  3. BioSpace